18 Jan Cynata Therapeutics
Ross Macdonald, Ph.D., CEO
April 13 | 12:00pm | BioCentriq Ballroom
Melbourne, Australia
(ASX:CYP)
Cynata Therapeutics is a clinical-stage stem cell and regenerative medicine company developing a therapeutic mesenchymal stem cell (MSC) platform technology, Cymerus™, utilizing induced pluripotent stem cells (iPSCs) as starting material. Cynata is the global leader in developing iPSC-derived cell therapies. A successful clinical trial in GvHD has been completed, meeting all safety and efficacy endpoints. The company is undertaking a Phase III clinical trial in osteoarthritis with further clinical trials underway in diabetic foot ulcers and expected to commence in 2023 in renal transplantation and in GvHD (following IND clearance from the U.S. FDA in 2022). The Cymerus technology addresses a critical shortcoming in conventional methods of production of MSCs for therapeutic use, which is the ability to achieve consistent, economic manufacture at commercial scale. Cymerus utilizes a proprietary process that is independent of donor limitations providing an off-the-shelf production platform for therapeutic product manufacture.
